Table 5.

Clinical characteristics of patients with extensive chronic graft-versus-host disease

All patients
(n = 68)
High-risk chronic GVHD (n = 25)Low-risk chronic GVHD (n = 43)
Organ involvement    
 Rash/scleroderma 52  (75%)* 17  (68%) 35  (81%)  
 Oral mucositis 33  (49%) 8  (32%) 25  (58%)  
 Ocular sicca 17  (25%) 3  (12%) 14  (33%)  
 Pulmonary disease 6  (9%) 0  (0%) 6  (14%)  
 Liver abnormalities 45  (66%) 21  (84%) 24  (56%) 
 Esophagitis 3  (4%) 1  (4%) 2  (5%) 
 Nausea/vomiting 10  (15%) 6  (24%) 4  (9%) 
 Diarrhea 20  (29%) 13  (52%) 7  (16%) 
 Arthralgias/arthritis 6  (9%) 2  (8%) 4  (9%) 
 Myositis 2  (3%) 0  (0%) 2  (5%) 
 Eosinophilia 23  (34%) 3  (12%) 20  (47%) 
 Effusions 3  (4%) 0  (0%) 3  (7%)  
Median day of onset after transplantation (range) Day 209 (90-655) Day 135 (90-383) Day 229 (98-655) 
1-year progression-free survival from diagnosis of chronic GVHD (95% CI) 47%  (35%-59%) 16%  (0%-30%) 64%  (50%-79%) 
All patients
(n = 68)
High-risk chronic GVHD (n = 25)Low-risk chronic GVHD (n = 43)
Organ involvement    
 Rash/scleroderma 52  (75%)* 17  (68%) 35  (81%)  
 Oral mucositis 33  (49%) 8  (32%) 25  (58%)  
 Ocular sicca 17  (25%) 3  (12%) 14  (33%)  
 Pulmonary disease 6  (9%) 0  (0%) 6  (14%)  
 Liver abnormalities 45  (66%) 21  (84%) 24  (56%) 
 Esophagitis 3  (4%) 1  (4%) 2  (5%) 
 Nausea/vomiting 10  (15%) 6  (24%) 4  (9%) 
 Diarrhea 20  (29%) 13  (52%) 7  (16%) 
 Arthralgias/arthritis 6  (9%) 2  (8%) 4  (9%) 
 Myositis 2  (3%) 0  (0%) 2  (5%) 
 Eosinophilia 23  (34%) 3  (12%) 20  (47%) 
 Effusions 3  (4%) 0  (0%) 3  (7%)  
Median day of onset after transplantation (range) Day 209 (90-655) Day 135 (90-383) Day 229 (98-655) 
1-year progression-free survival from diagnosis of chronic GVHD (95% CI) 47%  (35%-59%) 16%  (0%-30%) 64%  (50%-79%) 

Data presented as no. patients (with percentage of group in column in parentheses) unless indicated otherwise.

Close Modal

or Create an Account

Close Modal
Close Modal